Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan 15;201(2):233-40.
doi: 10.1086/649429.

Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes

Pamela A Moise  1 , Alan Forrest, Arnold S Bayer, Yan Q Xiong, Michael R Yeaman, George Sakoulas
Affiliations

Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes

Pamela A Moise et al. J Infect Dis. .

Abstract

Background: Vancomycin susceptibility, the accessory gene global regulator (agr) genotype and function, staphylococcal cassette chromosome (SCC) mec type, and susceptibility to cationic thrombin-induced platelet microbicidal protein 1 (tPMP-1) have been individually predictive of duration of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. This investigation evaluated the interrelationship of these factors with time to clearance of MRSA bacteremia during vancomycin therapy in patients without endocarditis.

Methods: Vancomycin minimum inhibitory concentration and in vitro killing, agr function (delta-hemolysin activity), agr group, SCCmec type, and survival in tPMP-1 killing assays were determined for 29 MRSA bacteremia isolates.

Results: Increased resistance to tPMP-1 killing was observed with agr group III MRSA (P = .025) and MRSA with reduced or absent agr function (P = .023). The median time to clearance of MRSA bacteremia was earlier for agr group III (3 days) versus group I (10.5 days) or II (15 days) (P = .001). In multivariate analysis, agr group II, reduced tPMP-1 killing in vitro, and prior vancomycin exposure were significant independent predictors of longer MRSA bacteremia duration.

Conclusions: Specific genotypic, phenotypic, and clinical parameters appear to correlate with persistent MRSA bacteremia. The interrelationship of these and other factors probably contributes to vancomycin-mediated clearance of MRSA bacteremia.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest: P.A.M. is currently employed by Cubist Pharmaceuticals. A.F. has received research funding from Theravance and Wyeth Pharmaceuticals. AS.B. has received research funding from Cubist Pharmaceuticals, Ortho-McNeil Pharmaceuticals, Novozyme Pharmaceuticals, Cerexa Pharmaceuticals, and Targanta Pharmaceuticals and is currently on the Cubist Scientific Advisory Board. M.R.Y. has received research funding from Pfizer, Novozyme Pharmaceuticals, Cubist Pharmaceuticals, and Amgen and is a cofounder and shareholder of NovaDigm Therapeutics. G.S. has received research funding from Cubist and Pfizer Pharmaceuticals; has been a consultant for Cubist, Pfizer, and Ortho McNeil; and has been on the speakers’ bureaus for Cubist, Pfizer, and Wyeth Pharmaceuticals.

Figures

Figure 1
Figure 1
Median time to clearance of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia by accessory gene global regulator (agr) specificity group. The median time to clearance was earlier for agr group III MRSA (3 days) (dashed line) than for group I (10.5 days) (dotted line) or group II (15 days) (solid line) MRSA (P =.001).
Figure 2
Figure 2
Kaplan-Meier analysis of time to clearance of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia by vancomycin in vitro killing activity. Upper (dotted) line represents 16 patients whose MRSA isolates demonstrated a reduction of <3.0 log10 colony-forming units per mL at 24 h; lower (solid) line represents 13 patients whose MRSA isolates demonstrated a reduction of ≥3.0 log10 colony-forming units per mL (P =.001).
Figure 3
Figure 3
Kaplan-Meier analysis of time to clearance of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia by thrombin-induced platelet microbicidal protein 1 (tPMP-1) activity. Upper (dotted) line represents 23 patients whose MRSA isolates demonstrated ≥15% MRSA survival at 2 h with exposure to 1 mg/L tPMP-1; lower (solid) line represents 6 patients whose MRSA isolates demonstrated <15% MRSA survival for the same exposure (P =.046).
Figure 4
Figure 4
Kaplan-Meier analysis of time to clearance of methicillin-resistant Staphylococcus aureus bacteremia by previous vancomycin use within 30 days of methicillin-resistant S. aureus bacteremia. Upper (dotted) line represents 12 patients who had received vancomycin previously; lower (solid) line represents 17 patients who had not received vancomycin previously (P =.020).
See this image and copyright information in PMC

References

    1. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC., Jr Agr group II genetic polymorphism in methicillin-resistant Staphylococcus aureus predicting failure of vancomycin therapy. Clin Infect Dis. 2004;38:1700–5. - PubMed
    1. Sakoulas G, Moise-Broder PA, Schentag JJ, Forrest A, Moellering RC, Jr, Eliopoulos GM. Relationship of vancomycin minimum inhibitory concentration (MIC) and bactericidal activity to the treatment efficacy of vancomycin in methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398–402. - PMC - PubMed
    1. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138–44. - PubMed
    1. Moise PA, Sakoulas G, Forrest A, et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2007;51:2582–6. - PMC - PubMed
    1. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193–200. - PubMed

Publication types

MeSH terms